Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Biological Replicate ID | Conc Unit | GR50 | GEC50 | GRmax | GRinf | GR Hill Coefficient | GR_AOC | GR r2 | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-474 | HER2amp | Luminal | Purvalanol A | CDK1 | CDK | 5906.067 | uM | inf | inf | 0.9890 | 0.9890 | 0.0000 | -0.0331 | -0.7588 | 0.6838 | |
CAMA-1 | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 10755.072 | uM | inf | inf | 0.2784 | 0.2784 | 0.0000 | 0.2357 | 0.5071 | 0.7300 | |
600MPE | HR+ | Luminal | Dactolisib | PI3K | PI3K | 12224.155 | uM | inf | inf | 0.7744 | 0.7744 | 0.0000 | 0.1982 | 0.2284 | 1.0378 | |
BT-474 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 12178.155 | uM | inf | inf | 0.7564 | 0.7564 | 0.0000 | 0.1748 | 0.0109 | 0.8489 | |
BT-20 | TNBC | Basal A | Methotrexate | DHFR | Metabolism | 5904.085 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0334 | -1.4110 | 1.2247 | |
BT-474 | HER2amp | Luminal | FTase Inhibitor I | Ftase | MAPK | 12056.154 | uM | inf | inf | 0.7002 | 0.7002 | 0.0000 | 0.2152 | -0.1183 | 0.9136 | |
600MPE | HR+ | Luminal | Glycyl-H-1152 | ROCK2 | 12224.16 | uM | inf | inf | 0.9729 | 0.9729 | 0.0000 | 0.0688 | 0.1842 | 0.7734 | ||
600MPE | HR+ | Luminal | 2-deoxyglucose | 13091.177 | uM | inf | inf | 0.9504 | 0.9504 | 0.0000 | 0.3143 | 0.0580 | 0.7004 | |||
AU565 | HER2amp | Luminal | Selumetinib | MEK | MAPK | 10880.155 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | -0.0108 | -0.1312 | 1.5205 | |
AU565 | HER2amp | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 5900.085 | uM | inf | inf | 0.5199 | 0.5199 | 0.0000 | 0.0667 | 0.2964 | 2.6391 | |
BT-20 | TNBC | Basal A | Pertuzumab | 5903.102 | mg/ml | inf | inf | 0.9324 | 0.9324 | 0.0000 | -0.0074 | -0.0405 | 1.2557 | |||
600MPE | HR+ | Luminal | AG1024 | IGF1R | RTK | 5898.066 | uM | inf | inf | 1.0423 | 1.0423 | 0.0000 | 0.0282 | 0.0610 | 0.6097 | |
600MPE | HR+ | Luminal | AG1024 | IGF1R | RTK | 5899.066 | uM | inf | inf | 1.0500 | 1.0500 | 0.0000 | 0.0165 | 0.0780 | 0.7056 | |
600MPE | HR+ | Luminal | PS-1145 | IKK | NFKB | 5899.065 | uM | inf | inf | 0.8491 | 0.8491 | 0.0000 | 0.1182 | 0.0000 | 1.0946 | |
BT-483 | HR+ | Luminal | PD184352 | MEK | MAPK | 11855.155 | uM | inf | inf | 0.7132 | 0.7132 | 0.0000 | 0.3205 | 0.0000 | 0.7873 | |
AU565 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5900.065 | uM | inf | inf | 0.9321 | 0.9321 | 0.0000 | -0.0050 | 0.3225 | 2.2026 | |
600MPE | HR+ | Luminal | Baicalein | Lipoxygenase | Metabolism | 12224.072 | uM | inf | inf | 0.8349 | 0.8349 | 0.0000 | 0.1299 | -0.0188 | 1.0105 | |
AU565 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 9035.018 | uM | inf | inf | 0.9083 | 0.9083 | 0.0000 | 0.0297 | 0.4162 | 2.1555 | |
BT-474 | HER2amp | Luminal | GSK461364 | PLK1 | PLK | 7798.001 | uM | inf | inf | 0.2083 | 0.2083 | 0.0000 | 0.2423 | 0.3086 | 1.3667 | |
BT-474 | HER2amp | Luminal | Glycyl-H-1152 | ROCK2 | 12291.169 | uM | inf | inf | 0.8955 | 0.8955 | 0.0000 | -0.0374 | 0.1290 | 0.3548 | ||
AU565 | HER2amp | Luminal | PS-1145 | IKK | NFKB | 5901.065 | uM | inf | inf | 0.9807 | 0.9807 | 0.0000 | 0.0027 | -0.0002 | 2.0114 | |
BT-483 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 5908.098 | uM | inf | inf | 0.7516 | 0.7516 | 0.0000 | 0.2163 | -0.0860 | 0.6091 | |
BT-474 | HER2amp | Luminal | Cetuximab | EGFR | ErbB | 7798.018 | uM | inf | inf | 1.0028 | 1.0028 | 0.0000 | -0.0260 | -0.7402 | 1.4461 | |
HCC1187 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 7811.018 | uM | inf | inf | 0.6946 | 0.6946 | 0.0000 | 0.1308 | -0.0060 | 0.4694 | |
HCC1187 | TNBC | Basal A | Celecoxib | COX2 | COX | 10518.136 | uM | inf | inf | 0.9091 | 0.9091 | 0.0000 | 0.0220 | 0.1805 | 1.2490 |